Company News: Page (1) of 1 - 02/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

NanoSphere Health Offers Six-Fold Improvement in Cannabinoid Bioavailability -- CFN Media

(February 14, 2018)

SEATTLE, Feb. 14, 2018 (GLOBE NEWSWIRE) -- CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering NanoSphere Health Sciences Inc. (CSE:NSHS) (CNSX:NSHS) (NSHS.CN) innovative delivery technology that solves key issues related to cannabinoid bioavailability. With an existing licensing agreement, the company is also well on its way to commercialization after spending more than a decade fine-tuning its technology--and developing products that have applications across an array of industries.

The U.S. cannabis industry is projected to exceed $50 billion in size over the coming years, according to Cowen & Co., driven by the legalization of adult-use cannabis in California and other states. While there are many opportunities for investors in the space, since they generate high-margin licensing revenue and don’t touch the plant, biotech firms developing innovative delivery mechanisms offer investors a compelling opportunity.

Cannabinoid Bioavailability

The issue of bioavailability is a major problem facing the medical cannabis industry. In a 2009 study, researchers found that cannabinoid bioavailability ranged from 2-56 percent for inhaled cannabis smoke and from 4-20 percent for orally consumed cannabis products. This variability among patients makes it difficult for physicians to prescribe cannabinoid-based products.

On a broader level, pharmaceutical industry experts estimate that approximately 40 percent of lipophilic (fat-soluble) medications fail in clinical trials because of their lack of water solubility and formulation instability. The insolubility, degeneration by digestive enzymes, pre-systemic metabolism, poor intestinal absorption, and removal from the liver prevents them from reaching threshold levels for activity. To a great extent, this first-pass metabolism also affects cannabinoid absorption.

Many companies have started developing cannabinoid delivery mechanisms aimed at improving bioavailability. But it’s a challenging task that requires extensive research and development. After developing these delivery mechanisms, they must also work to integrate them with existing cannabinoid products, which requires the participation of other cannabis industry participants. These challenges have left a gaping hole in the market for a reliable solution.

NanoSphere’s Technology

Researchers at NanoSphere Health have spent the past decade developing its patent-pending NanoSphere Delivery System™. The product successfully addresses the absorption issues associated with a wide variety of products, such as nutraceuticals, pharmaceuticals, over-the-counter medications, phytonutrients, and cannabinoids. Only recently did the company decide to enter the burgeoning cannabis industry, where its technology adapts seamlessly as a solution to questions surrounding pharmaceutical bioavailability.

The evidence-based NanoSphere Delivery System™ provides up to six times the bioavailability of conventional cannabinoids by transporting active ingredients directly into the bloodstream and cells using patent-pending natural lipid nanoparticle structures. In addition to the bioavailability improvements, the platform offers a high degree of biocompatibility, versatility, efficacy, and safety that makes it a natural choice for industry participants.

On January 23, the company announced that it signed an agreement to license its technology in the State of California. The Oakland-based licensee is a private-label manufacturer of pharmaceutical goods for more than 35 leading brands in the legal cannabis space and the agreement provides the manufacturer with a non-exclusive license to the patent-pending

NanoSphere Delivery System™ and its branded Evolve NanoSerum line.

Looking Ahead

NanoSphere Health Sciences Inc. (CSE: NSHS) represents a compelling investment opportunity in the legal cannabis industry. In addition to solving key issues relating to bioavailability, the company has already started to see some commercial wins after signing a deal with a large private-label manufacturer of pharmaceutical goods for more than 35 leading cannabis brands in the State of California.

Investors may want to take a closer look at the stock as a potential opportunity in the burgeoning cannabis industry, and in particular, California’s rapidly growing market.

For more information, visit the company’s website at www.nanospherehealth.com.

Please follow the link to read the full article:http://www.cannabisfn.com/nanosphere-health-offers-six-fold-improvement-cannabinoid-bioavailability/

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news. 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Contact

CFN Media


Frank Lane
206-369-7050
flane@cannabisfn.com


Page: 1


Related Keywords:
Related Sites: Creative Mac ,   DMN Newswire
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter

Our Privacy Policy --- @ Copyright, 2017 Digital Media Online, All Rights Reserved